IMPACT Therapeutics (HKG: 7630) announced that the European Commission (EC) has granted final marketing authorization for senaparib (overseas brand name: Sepalna), the company’s internally developed innovative drug, for the maintenance treatment of advanced epithelial ovarian, fallopian tube, and primary peritoneal cancer. The approval extends the drug’s regulatory footprint beyond China, where senaparib was authorized by the NMPA in January 2025 and added to the National Reimbursement Drug List (NRDL) in December 2025.
Regulatory Milestone
| Item | Detail |
|---|---|
| Agency | European Commission (EC) |
| Authorization Type | Final marketing authorization |
| Product | Senaparib (overseas brand name: Sepalna), capsules |
| Indication | Maintenance treatment of advanced epithelial ovarian, fallopian tube, and primary peritoneal cancer |
| Authorization Date | Announced 17 Nov 2026 |
| Prior Approvals | NMPA (China), January 2025 – first‑line maintenance therapy |
| Reimbursement | Included in China’s NRDL, December 2025 |
Drug Profile & Mechanism of Action
- Molecule: Senaparib, a novel PARP1/2 inhibitor (poly ADP‑ribose polymerase 1 and 2), independently developed by IMPACT Therapeutics.
- Mechanism: PARP inhibition blocks single‑strand DNA break repair, selectively targeting tumor cells with deficient homologous recombination — an established strategy in ovarian cancer maintenance therapy.
- Structural Innovation: A unique molecular structure that the company states ensures exceptional target selectivity and a wide therapeutic window, key differentiators in a class where tolerability governs chronic maintenance dosing.
- Formulation: Oral capsules.
- Setting: Maintenance therapy following response to platinum‑based chemotherapy — the dominant treatment paradigm in advanced ovarian cancer.
China Regulatory & Reimbursement History
- NMPA Approval (January 2025): Senaparib capsules were approved by China’s National Medical Products Administration as a first‑line maintenance therapy for adult patients with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer who have achieved a complete or partial response to platinum‑based chemotherapy.
- NRDL Inclusion (December 2025): The product was subsequently included in China’s National Reimbursement Drug List, supporting broad patient access in its home market.
- Development Trajectory: The EC decision marks the drug’s first disclosed authorization outside China, positioning Sepalna for commercial rollout in the European market.
Market Impact & Outlook
- EU Ovarian Cancer Landscape: Advanced epithelial ovarian cancer remains one of the deadliest gynecologic malignancies in Europe, with high relapse rates that make post‑chemotherapy maintenance a central and competitive treatment segment.
- PARP Inhibitor Competition: Senaparib joins an established class of PARP inhibitors used in ovarian cancer maintenance; its claimed selectivity and wide therapeutic window are positioned as differentiators, though head‑to‑head comparative data were not disclosed.
- Internationalization Signal: The final EC authorization extends IMPACT Therapeutics’ footprint beyond China and follows the company’s China reimbursement win, a sequence that supports both domestic volume growth and overseas expansion.
- Commercial Next Steps: Country‑level launch sequencing, pricing, and reimbursement negotiations within EU member states were not disclosed at announcement.
Forward‑Looking Statements
This brief contains forward‑looking statements regarding the commercialization of senaparib (Sepalna) in the European Union, reimbursement outcomes, clinical use, and market adoption. Actual results may differ due to risks including national pricing and reimbursement decisions, competitive dynamics, safety experience in broader patient populations, and manufacturing and supply execution. No sales forecasts or EU launch timelines have been disclosed.-Fineline Info & Tech
